CoChat
Sign Up
Cited by 25

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Bio-clickable, small extracellular vesicles-COCKTAIL therapy for ischemic stroke

Haroon, Khan, Ruan, Huitong, Zheng, Haoran, Wu, Shengju, Liu, Ze, Shi, Xiaojing, Tang, Yaohui, Yang, Guo-Yuan, Zhang, Zhijun·2023·Journal of Controlled Release
DOI 10.1016/j.jconrel.2023.10.003
Open this paper in CoChat — free account

Abstract

Delivering large therapeutic molecules via the blood-brain barrier to treat ischemic stroke remains challenging. NR2B9c is a potent neuroprotective peptide but it's safe and targeted delivery to the brain requires an efficient, natural, and non-immunogenic delivery technique. Small extracellular vesicles (sEVs) have shown great potential as a non-immunogenic, natural cargo delivery system; however, tailoring of its inefficient brain targeting is desired. Here, we coupled rabies virus glycoprotein 29 with sEVs surface via bio-orthogonal click chemistry reactions, followed by loading of NR2B9c, ultimately generating stroke-specific therapeutic COCKTAIL (sEVs-COCKTAIL). Primary neurons and Neuro-2a cells were cultured for in vitro and transient middle cerebral artery occlusion model was used for in vivo studies to evaluate neuron targeting and anti-ischemic stroke potential of the sEVs-COCKTAIL. Bio-clickable sEVs were selectively taken up by neurons but not glial cells. In the in vitro ischemic stroke model of oxygen-glucose deprivation, the sEVs-COCKTAIL exhibited remarkable potential against reactive oxygen species and cellular apoptosis. In vivo studies further demonstrated the brain targeting and increased half-life of bio-clickable sEVs, delivering NR2B9c to the ischemic brain and reducing stroke injury. Treatment with the sEVs-COCKTAIL significantly increased behavioral recovery and reduced neuronal apoptosis after transient middle cerebral artery occlusion. NR2B9c was de…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2023.10.003

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. Zhang, 2020, Programmable extracellular vesicles for macromolecule delivery and genome modifications, Dev. Cell, 55, 784, 10.1016/j.devcel.2020.11.007 · DOI
  2. Miller, 2002, Drug targeting. Breaking down barriers, Science, 297, 1116, 10.1126/science.297.5584.1116 · DOI
  3. Kristensen, 2020, Conjugation of therapeutic PSD-95 inhibitors to the cell-penetrating peptide tat affects blood-brain barrier adherence, uptake, and permeation, Pharmaceutics, 12, 10.3390/pharmaceutics12070661 · DOI
  4. Guo, 2022, Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety, Bioact Mater, 16, 204
  5. Macedo-Pereira, 2023, Digging the intercellular crosstalk via extracellular vesicles: may exosomes be the drug delivery solution for target glioblastoma?, J. Control. Release, 358, 98, 10.1016/j.jconrel.2023.04.038 · DOI
  6. Khan, 2021, Native and bioengineered exosomes for ischemic stroke therapy, Front. Cell Dev. Biol., 9, 619565, 10.3389/fcell.2021.619565 · DOI
  7. Li, 2021, Therapeutic application of exosomes in ischaemic stroke, Stroke Vasc Neurol, 6, 483, 10.1136/svn-2020-000419 · DOI
  8. Guo, 2021, Surface-modified engineered exosomes attenuated cerebral ischemia/reperfusion injury by targeting the delivery of quercetin towards impaired neurons, J. Nanobiotechnol., 19, 141, 10.1186/s12951-021-00879-4 · DOI
  9. Zheng, 2023, Advances in extracellular vesicle functionalization strategies for tissue regeneration, Bioact Mater, 25, 500
  10. Zhou, 2023, Intranasal delivery of BDNF-loaded small extracellular vesicles for cerebral ischemia therapy, J. Control. Release, 357, 1, 10.1016/j.jconrel.2023.03.033 · DOI
  11. Liu, 2022, Brain-targeted biomimetic Nanodecoys with neuroprotective effects for precise therapy of Parkinson’s disease, ACS Cent. Sci., 8, 1336, 10.1021/acscentsci.2c00741 · DOI
  12. Kwon, 2016, Neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries, ACS Nano, 10, 7926, 10.1021/acsnano.6b03858 · DOI
  13. You, 2022, Correction to targeted brain delivery of rabies virus glycoprotein 29-modified Deferoxamine-loaded nanoparticles reverses functional deficits in parkinsonian mice, ACS Nano, 16, 19605, 10.1021/acsnano.2c10134 · DOI
  14. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  15. Kim, 2019, Delivery of high mobility group Box-1 siRNA using brain-targeting exosomes for ischemic stroke therapy, J. Biomed. Nanotechnol., 15, 2401, 10.1166/jbn.2019.2866 · DOI
  16. Zheng, 2023, Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia, J. Control. Release, 353, 675, 10.1016/j.jconrel.2022.12.026 · DOI
  17. Sletten, 2009, Bioorthogonal chemistry: fishing for selectivity in a sea of functionality, Angew. Chem. Int. Ed. Eng., 48, 6974, 10.1002/anie.200900942 · DOI · Paper page
  18. Lai, 2014, Excitotoxicity and stroke: identifying novel targets for neuroprotection, Prog. Neurobiol., 115, 157, 10.1016/j.pneurobio.2013.11.006 · DOI · Paper page
  19. Ballarin, 2018, Discovery and development of NA-1 for the treatment of acute ischemic stroke, Acta Pharmacol. Sin., 39, 661, 10.1038/aps.2018.5 · DOI
  20. Ge, 2020, NMDARs in cell survival and death: implications in stroke pathogenesis and treatment, Trends Mol. Med., 26, 533, 10.1016/j.molmed.2020.03.001 · DOI
  21. Yu, 2018, Activatable protein nanoparticles for targeted delivery of therapeutic peptides, Adv. Mater., 30, 10.1002/adma.201803888 · DOI
  22. Martel, 2009, Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression, Channels (Austin), 3, 12, 10.4161/chan.3.1.7864 · DOI
  23. Zhou, 2017, Chimeric peptide tat-HA-NR2B9c improves regenerative repair after transient global ischemia, Front. Neurol., 8, 509, 10.3389/fneur.2017.00509 · DOI
  24. Cook, 2012, Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain, Nature, 483, 213, 10.1038/nature10841 · DOI
  25. Sun, 2008, Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat, Stroke, 39, 2544, 10.1161/STROKEAHA.107.506048 · DOI
  26. Teves, 2016, Efficacy of the PSD95 inhibitor tat-NR2B9c in mice requires dose translation between species, J. Cereb. Blood Flow Metab., 36, 555, 10.1177/0271678X15612099 · DOI
  27. Hill, 2012, Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet Neurol., 11, 942, 10.1016/S1474-4422(12)70225-9 · DOI
  28. Papadopoulou, 2013, The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders, Pharmaceuticals (Basel), 6, 32, 10.3390/ph6010032 · DOI
  29. Lv, 2018, Bioengineered Boronic Ester modified dextran polymer nanoparticles as reactive oxygen species responsive Nanocarrier for ischemic stroke treatment, ACS Nano, 12, 5417, 10.1021/acsnano.8b00477 · DOI
  30. Sebastian, 2021, Nondestructive production of exosomes loaded with ultrathin palladium nanosheets for targeted bio-orthogonal catalysis, Nat. Protoc., 16, 131, 10.1038/s41596-020-00406-z · DOI
  31. Dave, 2023, Mitochondria-containing extracellular vesicles (EV) reduce mouse brain infarct sizes and EV/HSP27 protect ischemic brain endothelial cultures, J. Control. Release, 354, 368, 10.1016/j.jconrel.2023.01.025 · DOI
  32. Gregorius, 2021, Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice, Basic Res. Cardiol., 116, 40, 10.1007/s00395-021-00881-9 · DOI
  33. Chen, 2015, Tat-NR2B9c prevents excitotoxic neuronal superoxide production, J. Cereb. Blood Flow Metab., 35, 739, 10.1038/jcbfm.2015.16 · DOI
  34. Li, 2022, M2 microglia-derived extracellular vesicles promote white matter repair and functional recovery via miR-23a-5p after cerebral ischemia in mice, Theranostics, 12, 3553, 10.7150/thno.68895 · DOI · Paper page
  35. Ruan, 2022, Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries, Acta Pharm. Sin. B, 13, 2202, 10.1016/j.apsb.2022.06.007 · DOI · Paper page
  36. Puzar Dominkus, 2018, PKH26 labeling of extracellular vesicles: characterization and cellular internalization of contaminating PKH26 nanoparticles, Biochim. Biophys. Acta Biomembr., 1860, 1350, 10.1016/j.bbamem.2018.03.013 · DOI
  37. Shi, 2021, Stroke subtype-dependent synapse elimination by reactive gliosis in mice, Nat. Commun., 12, 6943, 10.1038/s41467-021-27248-x · DOI
  38. Wang, 2022, Targeted delivery of fat extract by platelet membrane-cloaked nanocarriers for the treatment of ischemic stroke, J. Nanobiotechnol., 20, 249, 10.1186/s12951-022-01461-2 · DOI
  39. Aarts, 2002, Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions, Science, 298, 846, 10.1126/science.1072873 · DOI
  40. Yu, 2021, Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer’s disease, J. Drug Target., 29, 1128, 10.1080/1061186X.2021.1929257 · DOI
  41. Sajjanar, 2016, Effect of nicotinic acetylcholine receptor alpha 1 (nAChRalpha1) peptides on rabies virus infection in neuronal cells, Neuropeptides, 57, 59, 10.1016/j.npep.2015.11.090 · DOI
  42. Su, 2020, Rabies virus glycoprotein-amplified hierarchical targeted hybrids capable of magneto-electric penetration delivery to orthotopic brain tumor, J. Control. Release, 321, 159, 10.1016/j.jconrel.2020.02.018 · DOI
  43. Li, 2019, Trans-synaptic neural circuit-tracing with neurotropic viruses, Neurosci. Bull., 35, 909, 10.1007/s12264-019-00374-9 · DOI
  44. Kang, 2022, Transferrin receptor targeting segment T7 containing peptide gene delivery vectors for efficient transfection of brain tumor cells, Drug Deliv., 29, 2375, 10.1080/10717544.2022.2102696 · DOI
  45. Tang, 2023, A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration, Acta Biomater., 155, 521, 10.1016/j.actbio.2022.11.013 · DOI
  46. Kim, 2020, Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes, J. Control. Release, 317, 273, 10.1016/j.jconrel.2019.11.009 · DOI
  47. Spuch, 2012, LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Frontiers in, Physiology, 3
  48. Zhou, 2021, Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 13, 10.1002/wnan.1695 · DOI
  49. Liu, 2023, Engineering and characterization of an artificial drug-carrying vesicles nanoplatform for enhanced specifically targeted therapy of Glioblastoma, Adv. Mater.
  50. Martins, 2023, Stimuli-responsive multifunctional nanomedicine for enhanced glioblastoma chemotherapy augments multistage blood-to-brain trafficking and tumor targeting, Small, 19, 10.1002/smll.202300029 · DOI
  51. Xu, 2023, Recruiting T-cells toward the brain for enhanced glioblastoma immunotherapeutic efficacy by co-delivery of cytokines and immune checkpoint antibodies with macrophage-membrane-camouflaged Nanovesicles, Adv. Mater., 35, 10.1002/adma.202209785 · DOI
  52. Hermann, 2019, Animal models of ischemic stroke and their impact on drug discovery, Expert Opin. Drug Discovery, 14, 315, 10.1080/17460441.2019.1573984 · DOI
  53. Ruan, 2023, Engineered extracellular vesicles for ischemic stroke treatment, Innovation (Camb), 4, 100394
  54. Li, 2023, Extracellular vesicle-encapsulated AAVs for therapeutic gene delivery to the heart, Circulation, 146, A12178
  55. Yin, 2022, Engineered Nanoerythrocytes alleviate central nervous system inflammation by regulating the polarization of inflammatory microglia, Adv. Mater., 34, 10.1002/adma.202201322 · DOI
  56. Dumbrava, 2022, Mesenchymal stromal cell-derived small extracellular vesicles promote neurological recovery and brain remodeling after distal middle cerebral artery occlusion in aged rats, Geroscience, 44, 293, 10.1007/s11357-021-00483-2 · DOI
  57. Wang, 2020, Mesenchymal stromal cell-derived small extracellular vesicles induce ischemic neuroprotection by modulating leukocytes and specifically neutrophils, Stroke, 51, 1825, 10.1161/STROKEAHA.119.028012 · DOI
  58. Pan, 2023, M2 microglial extracellular vesicles attenuated blood-brain barrier disruption via MiR-23a-5p in Cerebral Ischemic Mice, Aging Dis.

Cited by

Sorted by citations

Metadata

Authors
Haroon, K., Ruan, H., Zheng, H., Wu, S., Liu, Z., Shi, X., Tang, Y., Yang, G.-Y., & Zhang, Z.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-11
Volume
363
Pages
585-596
ISSN
0168-3659
DOI
10.1016/j.jconrel.2023.10.003
Cited by
25
References
5
Language
en
Licence
Funders
  • National Natural Science Foundation of China (82271320, 81974179, 82003658, 82071284)
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Shanghai Municipal Education Commission
  • Shanghai Education Development Foundation
  • National Key Research and Development Program of China (2019YFA0112000, 2022YFA1603604)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review